Study | Year | Country | Study design | Number (Male) | Tumor stage | Cut-off for high CONUT group | Prevalence of high CONUT score | End points | Follow-up (median, months) | Qualitya |
---|---|---|---|---|---|---|---|---|---|---|
Kuroda [7] | 2018 | Japan | Retrospective Single center | 416 (267) | I: 275 II: 81 III: 60 | ≥4 | 14.9% | OS CSS RFS Complications | 61.2 | 6 |
Zheng [8] | 2018 | China | Retrospective Single center | 532 (403) | I: 165 II: 123 III: 244 | 0–1 (normal) 2–4 (light) ≥5 (moderate or severe) | 54.7% 34.4% 10.9% | OS RFS | 60 | 7 |
Liu [9] | 2018 | China | Retrospective Single center | 697 (457) | II: 194 III: 503 | ≥3 | 31.1% | CSS Complications | 36 | 6 |
Ryo [13] | 2018 | Japan | Retrospective Multi-center | 626 (435) | II: 281 III: 345 | ≥2 | 46.2% | OS RFS Complications | 49.2 | 7 |
Suzuki [14] | 2018 | Japan | Retrospective Single center | 211 (141) | I: 132 II: 53 III: 26 | ≥5 | 17.1% | OS CSS Complications | 47 | 6 |